

EU Regulatory Update

**International Medical Device Regulators Forum 28th Session
Sapporo, Japan – 16 September 2025**

**Nada Alkhayat
European Commission
DG Health and Food Safety**





Priorities

Continue	Implementation of the MDR/IVDR
Accelerate	Short-term actions: both legislative and non-legislative
Finalise	Targeted evaluation and revision (planned for Q4 2025)

Implementation of MDR/IVDR



Coherent and pragmatic application of **extended transitional provisions** for different types of devices to prevent potential shortages of existing and new/innovative devices



Availability and capacity of notified bodies (currently 50 for the MDR and 18 for the IVDR in the NANDO information system)



Availability of harmonised standards (currently 32 for the MDR and 17 for the IVDR in the OJEU – including ISO 13485 (QMS), IEC 60601 series, ISO 14971 (RMS) *(more publications under preparation)*)



Adoption and enforcement of implementing and delegated acts for different aspects of the Regulations (most-recently: Master-UDI delegated act, Electronic instructions for use, orphan expert panel...), short-term measures



MDCG guidance documents (updates and new)



Development of EUDAMED ongoing



Short-term actions

Legislative and non-legislative



e-IFUs for medical devices (Reg. 2021/2226)

- Amended by Commission **Implementing Regulation (EU) 2025/1234** on 16 July 2025
- **Scope of the amendment:** broadly expanded to
 - ✓ allowing possibility to issue e-IFUs for most **medical devices intended for professional users**,
 - ✓ Inclusion of **devices without an intended medical purpose** listed in Annex XVI of Regulation (EU) 2017/745,
- **Streamlined the conformity assessment process** by removing the separate requirement for Notified Body review, eliminating redundancy with other assessment activities.
 - ✓ Including **link to e-IFUs** in the UDI module of **EUDAMED**.



Note: dual-use medical devices (both professional and lay-user): the IFU intended for the lay person must be provided in paper form.



Designation of a **paediatrics and rare disease expert panel**



Image credit: Adobe images

- Amended by Commission **Implementing Decision (EU) 2025/1324** on 7 July 2025
- **Scope of the amendment:**
 - ✓ Designation of a new expert panel dedicated to **paediatrics and rare diseases**,
 - ✓ Updated administrative rules: work of sub-groups and procedures for designating rapporteurs,
 - ✓ Clarification of the role of the European Medicines Agency (EMA), now fully responsible for the panels' secretariat.
- **Aim:** to foster innovation and accessibility by offering expertise on the safety and performance of devices for rare diseases and children.
- **Expected output:** The new panel will enhance the regulatory process by providing opinions to support manufacturers and notified bodies under the EU Medical Device Regulation.




Short-term actions underway



Short-term actions – Legislative



 **1** Implementing regulation for e-IFUs for medical devices

- Public feedback closed
- Planned adoption date: **Q2 2025**

 **2** Establishment of an Expert Panel on orphan and paediatric devices

- Planned adoption date: **Q2 2025**

3 **Reclassification** of well-established technologies (WET)

- Request for evidence: processing input
- Planned adoption date: **Q4 2025**

4 Expansion of the **list** of well-established technologies (WET)

- Request for evidence: processing input
- Planned adoption date: **Q4 2025**

5 Implementing rules regarding requirements to be met by Notified Bodies

- Identified high priorities and ongoing discussion on input received
- Workshop with stakeholders (20 Feb 2025)
- Planned adoption date: **Q4 2025**



Short-term actions – Non-legislative



- 1 Guidance on **breakthrough technologies (BtX)**
- 2 Guidance on **orphan IVDs**
- 3 Guidance on **sampling of technical documentation**
- 4 Guidance on **certificates under conditions**
- 5 Guidance on **structured dialogue**

- 6 **IMDRF Guidance of high priority:** Pre-Determined Change Control Plans, Good Machine Learning Practices, Quality Management Systems, IVD Clinical Evidence and the Reliance Playbook
- 7 **MDSAP mapping activities** (NBCG-Med and MDCG)
- 8 **Support to other activities** : e.g. Horizon scanning, orphan devices, JAMS 2.0



EUDAMED

European Database for Medical Devices



Gradual roll out and timelines

Draft planning of the next steps

2025

2026

2027

Q2 2025

Q3 2025

Q4 2025

Q1 2026

Q2 2026

Q3 2026

Q4 2026

Q1 2027

*Finalization of MVP
Audit on 4 Modules*

NonMVP Mandatory Use Development for 4 Modules

Mandatory use of Actor, UDI/Devices, NBs & Certificates, MSU

Market surveillance

Vigilance

MVP Audit Vigilance

NonMVP Mandatory Use Development Vigilance

CI/PS

Mandatory use of Vigilance module

Certificates

UDI/Devices

*Publication of the notice of functionality in OJEU (Actor,
UDI/Device, NB&CRF, MSU)*

Actors



Register
now!

Gradual roll out and timelines

Registration obligations timelines



Actor registration:

Now: voluntary
use

6 Months after
publication of the
notice in the
OJEU:
mandatory use

Market

No voluntary use

6 Months after
publication of the
notice in the
OJEU: mandatory
use of the module

Device registration:

Now: voluntary
use

6 Months after
publication of the
notice in the
OJEU: mandatory
use of the module

Certificate

Now: voluntary use

6 Months after
publication of the
notice in the OJEU:
mandatory use of
the module





Three hybrid workshops organised by COM



21 May 2025



Stuttgart (DE)



08 October 2025

Rome (IT)



03 December 2025

Brussels (BE)

Register NOW!

All actors are
welcome



<https://tinyurl.com/4k864h5c>

What to expect:

- Hands-on guidance on MDR/IVDR requirements related to EUDAMED
- Live navigation through the first four modules
- Practical aspects in data management and legal compliance



Developments in the digital space



Recent digital guidance

Software Qualification & Classification



[MDCG 2019-11 rev.1](#)




- Medical purpose beyond diagnostic devices to include **digital therapeutics**, new examples including **Class I**
- Clarifications on **modular approach** to placing on the market
- Interplay with European **Health Data Space**

Wearable and sensor technologies



[MDCG 2023-4](#)




- Differentiation of different types of devices working in **combination** (system, combined, integral)
- Recognising that hardware may not be a medical device itself (**consumer product**)
- **Clinical and conformity** requirements for different 'scenarios'

Medical Device AI (MDAI)



[MDCG 2025-6](#)



- Interplay with horizontal AI Act & clarification on **risk class applicability**
- Integrate **AI Act requirements** into existing MDR and IVDR pathways
- QMS, Risk-Management, Data Governance, Pre-determined Change Control

App store and manufacturer online responsibilities



[MDCG 2025-4](#)



- Host vs distributor/importer **roles**
- **Transparency** towards users: clear intended purpose, CE mark, UDI & documentation
- Mechanisms for **reporting & traceability**



Horizon Scanning System - MDs & IVDs


 **HADEA/2024/OP/0024**

Objectives

Put in place a **horizon scanning system**  in the area of **MDs and IVDs**   in order to maintain an up-to-date overview of **new & emerging technologies** .

Aim:

-  **Screen available sources** for novel & emerging technologies
-  **Assess features** that may impact medical devices & IVDs
-  **Identify opportunities, risks & trends** related to these technologies

This horizon scanning was identified as a need in the context of implementing **MDR/IVDR legislation** to support **competitiveness & innovation** in the EU market, while ensuring a **high level of protection of health** for patients and users.  

 **Contract value:** €896 400

 **Contractor:** TECHNOPOLIS FRANCE

 **Period:** 30 months (contract signed on 06/06/2025)

 **Status:** Ongoing

  [Read the contract award notice](#) for more details.



Call for Evidence – EU cardiovascular health plan

The plan will address:


-  Prevention
-  Early detection & screening
-  Treatment & rehabilitation

Next to using the opportunities offered by **new technologies** (   including digital & AI), **innovation**  and **personalised tools** , the plan will also address the current **research & innovation gap** in **cardiovascular health** .

 **Stakeholders are invited to submit feedback by 15 September**  **31**. For more info, see: [HEALTH AND FOOD SAFETY - EU Cardiovascular Health Plan: Call for Evidence](#)







Targeted evaluation and follow-up





Call for evidence: Future oriented

*The initiative aims to **simplify** and **streamline** the regulatory framework, make it more **cost-efficient** and **proportionate**, while **preserving a high level of public health and patient safety** and the overall structure of the current regulatory framework.*


-  **reduce** administrative burden including **reporting** obligations,
-  **enhance** the **predictability** and **cost-efficiency** of notified bodies certification processes,
-  make the conformity assessment **requirements more proportionate**, especially for low and medium risk devices and those that cater to special patient needs,
-  enable further **digitalisation**,
-  **streamline** procedures including governance,
-  enable the EU medical device sector to benefit from **international cooperation** including reliance, where appropriate
- better **align** with **other** relevant **legislation**.

8 September - 6 October
2025



<https://tinyurl.com/3tzhn4u>





Thank you

For further information regarding EU medical device regulations and developments: [Medical Devices - New regulations - European Commission](#)

For specific questions: sante-med-dev@ec.europa.eu